Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Review Article

RNA结合蛋白HuR：抗癌治疗的有希望的药物靶标

卷 19, 期 5, 2019

页: [382 - 399] 页: 18

弟呕挨: 10.2174/1568009618666181031145953

价格: $65

conference banner
摘要

mRNA的稳定性是控制真核基因表达和功能调节的关键因素之一。人抗原R（HuR）是一种RNA结合蛋白，其调节其靶mRNA的稳定性，翻译和细胞核到细胞质的穿梭。虽然HuR通常定位于细胞核内，但已显示HuR结合细胞核中的mRNA，然后将mRNA护送至细胞质，其中HuR保护它们免于降解。它含有几个RNA识别基序，它们特异性结合靶mRNA的3''非翻译区内的腺苷酸和富含尿苷酸的区域，以介导其作用。许多HuR靶mRNA编码对细胞生长，肿瘤发生，血管生成，肿瘤炎症，侵袭和转移重要的蛋白质。已知HuR过表达与许多肿瘤类型中的高度恶性肿瘤和不良预后很好地相关。因此，HuR已成为癌症治疗的有吸引力的药物靶标。已经通过高通量筛选鉴定了新的小分子HuR抑制剂，并且已经开发了用于将HuR siRNA靶向递送至肿瘤细胞的新制剂，其具有有希望的抗癌活性。本综述总结了HuR在癌症发展，进展和治疗反应差的重要作用。我们将讨论治疗性靶向HuR的潜力和挑战。

关键词:

« Previous Next »
图形摘要

[1]
Orphanides, G.; Reinberg, D. A unified theory of gene expression. Cell, 2002, 108(4), 439-451.
[2]
Mitchell, P.; Tollervey, D. mRNA stability in eukaryotes. Curr. Opin. Genet. Dev., 2000, 10(2), 193-198.
[3]
Pullmann, R., Jr; Kim, H.H.; Abdelmohsen, K.; Lal, A.; Martindale, J.L.; Yang, X.; Gorospe, M. Analysis of stability and translation regulatory RBP expression through binding to cognate mRNAs. Mol. Cell. Biol., 2007, 27(18), 6265-6278.
[4]
Keene, J.D. RNA regulons: Coordination of post-transcriptional events. Nat. Rev. Genet., 2007, 8(7), 533-543.
[5]
Valencia-Sanchez, M.A.; Liu, J.; Hannon, G.J.; Parker, R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev., 2006, 20(5), 515-524.
[6]
Brooks, S.A.; Blackshear, P.J. Tristetraprolin (TTP): Interactions with mRNA and proteins, and current thoughts on mechanisms of action. Biochim. Biophys. Acta, 2013, 1829(6-7), 666-679.
[7]
Sanduja, S.; Blanco, F.F.; Dixon, D.A. The roles of TTP and BRF proteins in regulated mRNA decay. Wiley Interdiscip. Rev. RNA, 2011, 2(1), 42-57.
[8]
Stoecklin, G.; Mayo, T.; Anderson, P. ARE-mRNA degradation requires the 5′-3′ decay pathway. EMBO Rep., 2006, 7(1), 72-77.
[9]
Gherzi, R.; Lee, K.Y.; Briata, P.; Wegmuller, D.; Moroni, C.; Karin, M.; Chen, C.Y. A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol. Cell, 2004, 14(5), 571-583.
[10]
Vindry, C.; Vo Ngoc, L.; Kruys, V.; Gueydan, C. RNA-binding protein-mediated post-transcriptional controls of gene expression: Integration of molecular mechanisms at the 3′ end of mRNAs? Biochem. Pharmacol., 2014, 89(4), 431-440.
[11]
Ma, W.J.; Cheng, S.; Campbell, C.; Wright, A.; Furneaux, H. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J. Biol. Chem., 1996, 271(14), 8144-8151.
[12]
Ma, W.J.; Furneaux, H. Localization of the human HuR gene to chromosome 19p13.2. Hum. Genet., 1997, 99(1), 32-33.
[13]
Burd, C.G.; Dreyfuss, G. Conserved structures and diversity of functions of RNA-binding proteins. Science (New York, NY.), 1994, 265(5172), 615-621.
[14]
Ma, W.J.; Chung, S.; Furneaux, H. The Elav-like proteins bind to AU-rich elements and to the poly(A) tail of mRNA. Nucleic Acids Res., 1997, 25(18), 3564-3569.
[15]
Lopez de Silanes, I.; Zhan, M.; Lal, A.; Yang, X.; Gorospe, M. Identification of a target RNA motif for RNA-binding protein HuR. Proc. Natl. Acad. Sci. USA, 2004, 101(9), 2987-2992.
[16]
Brennan, C.M.; Steitz, J.A. HuR and mRNA stability. Cell. Mol. Life Sci., 2001, 58(2), 266-277.
[17]
Abdelmohsen, K.; Kuwano, Y.; Kim, H.H.; Gorospe, M. Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: Implications for cellular senescence. Biol. Chem., 2008, 389(3), 243-255.
[18]
Hinman, M.N.; Lou, H. Diverse molecular functions of Hu proteins. Cell. Mol. Life Sci., 2008, 65(20), 3168-3181.
[19]
Lutz, C.S.; Moreira, A. Alternative mRNA polyadenylation in eukaryotes: An effective regulator of gene expression. Wiley Interdiscip. Rev. RNA, 2011, 2(1), 23-31.
[20]
Zhu, H.; Zhou, H.L.; Hasman, R.A.; Lou, H. Hu proteins regulate polyadenylation by blocking sites containing U-rich sequences. J. Biol. Chem., 2007, 282(4), 2203-2210.
[21]
Halees, A.S.; El-Badrawi, R.; Khabar, K.S. ARED Organism: expansion of ARED reveals AU-rich element cluster variations between human and mouse. Nucleic Acids Res., 2008, 36(Database issue), D137-D140.
[22]
Audic, Y.; Hartley, R.S. Post-transcriptional regulation in cancer. Biol. Cell, 2004, 96(7), 479-498.
[23]
Lagnado, C.A.; Brown, C.Y.; Goodali, G.J. AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: the functional sequence within AU-rich elements may be UUAUUUA(U/A)(U/A). Mol. Cell. Biol., 1994, 14(12), 7984-7995.
[24]
Abdelmohsen, K.; Gorospe, M. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip. Rev. RNA, 2010, 1(2), 214-219.
[25]
Izquierdo, J.M. Hu antigen R (HuR) functions as an alternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition. J. Biol. Chem., 2008, 283(27), 19077-19084.
[26]
Chen, C.Y.; Gherzi, R.; Ong, S.E.; Chan, E.L.; Raijmakers, R.; Pruijn, G.J.; Stoecklin, G.; Moroni, C.; Mann, M.; Karin, M. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell, 2001, 107(4), 451-464.
[27]
Lal, A.; Mazan-Mamczarz, K.; Kawai, T.; Yang, X.; Martindale, J.L.; Gorospe, M. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J., 2004, 23(15), 3092-3102.
[28]
Young, L.E.; Moore, A.E.; Sokol, L.; Meisner-Kober, N.; Dixon, D.A. The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. Mol. Cancer Res., 2012, 10(1), 167-180.
[29]
Durie, D.; Lewis, S.M.; Liwak, U.; Kisilewicz, M.; Gorospe, M.; Holcik, M. RNA-binding protein HuR mediates cytoprotection through stimulation of XIAP translation. Oncogene, 2011, 30(12), 1460-1469.
[30]
Bhattacharyya, S.N.; Habermacher, R.; Martine, U.; Closs, E.I.; Filipowicz, W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell, 2006, 125(6), 1111-1124.
[31]
Kawai, T.; Lal, A.; Yang, X.; Galban, S.; Mazan-Mamczarz, K.; Gorospe, M. Translational control of cytochrome c by RNA-binding proteins TIA-1 and HuR. Mol. Cell. Biol., 2006, 26(8), 3295-3307.
[32]
Kullman, M.; Gopfert, U.; Siewe, B.; Hengst, L. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5’UTR. Genes Dev., 2002, 16(23), 3087-3099.
[33]
Meng, Z.; Jackson, N.L.; Choi, H.; King, P.H.; Emanuel, P.D.; Blume, S.W. Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-1R translational control in human breast tumor cells. J. Cell. Physiol., 2008, 217(1), 172-183.
[34]
Kim, H.H.; Kuwano, Y.; Srikantan, S.; Lee, E.K.; Martindale, J.L.; Gorospe, M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev., 2009, 23(15), 1743-1748.
[35]
Abdelmohsen, K.; Srikantan, S.; Kuwano, Y.; Gorospe, M. miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc. Natl. Acad. Sci. USA, 2008, 105(51), 20297-20302.
[36]
Marasa, B.S.; Srikantan, S.; Martindale, J.L.; Kim, M.M.; Lee, E.K.; Gorospe, M.; Abdelmohsen, K. MicroRNA profiling in human diploid fibroblasts uncovers miR-519 role in replicative senescence. Aging (Albany N.Y.), 2010, 2(6), 333-343.
[37]
Abdelmohsen, K.; Kim, M.M.; Srikantan, S.; Mercken, E.M.; Brennan, S.E.; Wilson, G.M.; de Cabo, R.; Gorospe, M. miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle, 2010, 9(7), 1354-1359.
[38]
Guo, X.; Wu, Y.; Hartley, R.S. MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol., 2009, 6(5), 575-583.
[39]
Xu, F.; Zhang, X.; Lei, Y.; Liu, X.; Liu, Z.; Tong, T.; Wang, W. Loss of repression of HuR translation by miR-16 may be responsible for the elevation of HuR in human breast carcinoma. J. Cell. Biochem., 2010, 111(3), 727-734.
[40]
Kojima, K.; Fujita, Y.; Nozawa, Y.; Deguchi, T.; Ito, M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate, 2010, 70(14), 1501-1512.
[41]
AL-Ahmadi. W.; Al-Ghamdi, M.; Al-Souhibani, N.; Khabar, K.S. miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. J. Pathol., 2013, 230(1), 28-38.
[42]
Srikantan, S.; Tominaga, K.; Gorospe, M. Functional interplay between RNA-binding protein HuR and microRNAs. Curr. Protein Pept. Sci., 2012, 13(4), 372-379.
[43]
Al-Ahmadi, W.; Al-Ghamdi, M.; Al-Haj, L.; Al-Saif, M.; Khabar, K.S. Alternative polyadenylation variants of the RNA binding protein HuR: Abundance, role of AU-rich elements and auto-regulation. Nucleic Acids Res., 2009, 37(11), 3612-3624.
[44]
Yi, J.; Chang, N.; Liu, X.; Guo, G.; Xue, L.; Tong, T.; Gorospe, M.; Wang, W. Reduced nuclear export of HuR mRNA by HuR is linked to the loss of HuR in replicative senescence. Nucleic Acids Res., 2010, 38(5), 1547-1558.
[45]
Wang, H.; Molfenter, J.; Zhu, H.; Lou, H. Promotion of exon 6 inclusion in HuD pre-mRNA by Hu protein family members. Nucleic Acids Res., 2010, 38(11), 3760-3770.
[46]
Fan, X.C.; Steitz, J.A. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J., 1998, 17(12), 3448-3460.
[47]
Fan, X.C.; Steitz, J.A. HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc. Natl. Acad. Sci. USA, 1998, 95(26), 15293-15298.
[48]
Gallouzi, I.E.; Brennan, C.M.; Stenberg, M.G.; Swanson, M.S.; Eversole, A.; Maizels, N.; Steitz, J.A. HuR binding to cytoplasmic mRNA is perturbed by heat shock. Proc. Natl. Acad. Sci. USA, 2000, 97(7), 3073-3078.
[49]
Doller, A. Akool El-S; Huwiler, A.; Muller, R.; Radeke, H.H.; Pfeilschifter, J.; Eberhardt, W. Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol. Cell. Biol., 2008, 28(8), 2608-2625.
[50]
Doller, A.; Huwiler, A.; Muller, R.; Radeke, H.H.; Pfeilschifter, J.; Eberhardt, W. Protein kinase C alpha-dependent phosphorylation of the mRNA-stabilizing factor HuR: Implications for posttranscriptional regulation of cyclooxygenase-2. Mol. Biol. Cell, 2007, 18(6), 2137-2148.
[51]
Wang, W.; Fan, J.; Yang, X.; Furer-Galban, S.; Lopez de Silanes, I.; von Kobbe, C.; Guo, J.; Georas, S.N.; Foufelle, F.; Hardie, D.G.; Carling, D.; Gorospe, M. AMP-activated kinase regulates cytoplasmic HuR. Mol. Cell. Biol., 2002, 22(10), 3425-3436.
[52]
Kim, H.H.; Gorospe, M. Phosphorylated HuR shuttles in cycles. Cell Cycle, 2008, 7(20), 3124-3126.
[53]
Kim, H.H.; Abdelmohsen, K.; Lal, A.; Pullmann, R., Jr; Yang, X.; Galban, S.; Srikantan, S.; Martindale, J.L.; Blethrow, J.; Shokat, K.M.; Gorospe, M. Nuclear HuR accumulation through phosphorylation by Cdk1. Genes Dev., 2008, 22(13), 1804-1815.
[54]
Abdelmohsen, K.; Pullmann, R., Jr; Lal, A.; Kim, H.H.; Galban, S.; Yang, X.; Blethrow, J.D.; Walker, M.; Shbert, J.; Gillespie, D.A.; Furneaux, H.; Gorospe, M. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol. Cell, 2007, 25(4), 543-557.
[55]
Doller, A.; Schlepckow, K.; Schwalbe, H.; Pfeilschifter, J.; Eberhardt, W. Tandem phosphorylation of serines 221 and 318 by protein kinase Cdelta coordinates mRNA binding and nucleocytoplasmic shuttling of HuR. Mol. Cell. Biol., 2010, 30(6), 1397-1410.
[56]
Doller, A.; Pfeilschifter, J.; Eberhardt, W. Signalling pathways regulating nucleo-cytoplasmic shuttling of the mRNA-binding protein HuR. Cell. Signal., 2008, 20(12), 2165-2173.
[57]
Amadio, M.; Bucolo, C.; Leggio, G.M.; Drago, F.; Govoni, S.; Pascale, A. The PKCβ/HuR/VEGF pathway I diabetic retinopathy. Biochem. Pharmacol., 2010, 80(8), 1230-1237.
[58]
Lafarga, V.; Cuadrado, A.; Lopez de Silanes, I.; Bengoechea, R.; Fernandez-Capetillo, O.; Nebreda, A.R. p38 mitogen-activated protein kinase- and HuR-dependent stabilization of p21 (Cip1) mRNA mediates the G(1)/S checkpoint. Mol. Cell. Biol., 2009, 29(16), 4341-4351.
[59]
Li, H.; Park, S.; Kilburn, B.; Jelinek, M.A.; Henschen-Edman, A.; Aswad, D.W.; Stallcup, M.R.; Laird-Offringa, I.A. Lipopolusaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM11 coactivator-associated arginiemethyltransferase. J. Biol. Chem., 2002, 277(47), 44623-45430.
[60]
Fujiwara, T.; Mori, Y.; Chu, D.; Koyama, Y.; Miyata, S.; Tanaka, H.; Yachi, K.; Kubo, T.; Yoshikawa, H.; Tohyama, M. CARM1 regulates proliferation of PC12 cells by methylating huD. Mol. Cell. Biol., 2006, 26(6), 2273-2285.
[61]
Pang, L.; Tian, H.; Chang, N.; Yi, J.; Xue, L.; Jiang, B.; Gorospe, M.; Zhang, X.; Wang, W. Loss of CARM1 is linked to reduced HuR function in replicative senescence. BMC Mol. Biol., 2013, 14, 15.
[62]
Abdelmohsen, K.; Srikantan, S.; Yang, X.; Lal, A.; Kim, H.H.; Kuwano, Y.; Galban, S.; Becker, K.G.; Kamara, D.; de Cabo, R.; Gorospe, M. Ubiquitin-mediated proteolysis of HuR by heat shock. EMBO J., 2009, 28(9), 1271-1282.
[63]
Lucchesi, C.; Sheikh, M.S.; Huang, Y. Negative regulation of RNA-binding protein HuR by tumor-suppressor ECRG2. Oncogene, 2016, 35(20), 2565-2573.
[64]
Zhou, H.L.; Geng, C.; Luo, G.; Lou, H. The p97-UBXD8 complex destabilizes mRNA by promoting release of ubiquitinated HuR from mRNP. Genes Dev., 2013, 27(9), 1046-1058.
[65]
Zhou, L.; Zhang, W.; Sun, Y.; Jia, L. Protein neddylation and its alterations in human cancers for targeted therapy. Cell. Signal., 2018, 44, 92-102.
[66]
Embade, N.; Fernandez-Ramos, D.; Varlea-Rey, M.; Beraza, N.; Sini, M.; Gutierrez de Juan, V.; Woodhoo, A.; Martinez-Lopez, N.; Rodriguez-Iruretagoyena, B.; Bustamante, F.J.; de la Hoz, A.B.; Carracedo, A.; Xirodimas, D.P.; Rodriguez, M.S.; Lu, S.C.; Mato, J.M.; Martinez-Chantar, M.L. Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology, 2012, 55(4), 1237-1248.
[67]
de Sousa, G.F. Lima, Mde, A.; Custodio, D.F.; Freitas, V.M.; Monteiro, G. Chemogenomic study of carboplatin in Saccharomyces cerevisiae: inhibition of the NEDDylation process overcomes cellular resistance mediated by HuR and Cullin proteins. PLoS One, 2015, 10(12), e0145377.
[68]
Nabors, L.B.; Gillespie, G.Y.; Harkins, L.; King, P.H. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res., 2001, 61(5), 2154-2161.
[69]
Dixon, D.A.; Tolley, N.D.; King, P.H.; Nabors, L.B.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J. Clin. Invest., 2001, 108(11), 1657-1665.
[70]
Wang, H.; Ding, N.; Guo, J.; Xia, J.; Ruan, Y. Dysregulation of TPP and HuR plays an important role in cancers. Tumour Biol., 2016, 37(11), 14451-14461.
[71]
Heinonen, M.; Bono, P.; Narko, K.; Chang, S.H.; Lundin, J.; Joensuu, H.; Furneaux, H.; Hla, T.; Haglund, C.; Ristimaki, A. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res., 2005, 65(6), 2157-2161.
[72]
Lim, S.J.; Kim, H.J.; Kim, J.Y.; Park, K.; Lee, C.M. Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int. J. Gynecol. Pathol., 2007, 26(3), 229-234.
[73]
Denkert, C.; Koch, I.; von Keyserkingk, N.; Noske, A.; Niesporek, S.; Dietel, M.; Weichert, W. Expression of the ELAV-like protein HuR in human colon cancer: Association with tumor stage and cyclooxygenase-2. Mod. Pathol., 2006, 19(9), 1261-1269.
[74]
Lauriola, L.; Granone, P.; Ramella, S.; Lanza, P.; Ranelletti, F.O. Expression of the RNA-binding protein HuR and its clinical significance in human stage I and II lung adenocarcinoma. Histol. Histopathol., 2012, 27(5), 617-626.
[75]
Denkert, C.; Weichert, W.; Pest, S.; Koch, I.; Licht, D.; Kobel, M.; Reles, A.; Sehouli, J.; Dietel, M.; Hauptmann, S. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res., 2004, 64(1), 189-195.
[76]
Liang, P.I.; Li, W.M.; Wang, Y.H.; Wu, T.F.; Wu, W.R.; Liao, A.C.; Shen, K.H.; Wei, Y.C.; Hsing, C.H.; Shiue, Y.L.; Huang, H.Y.; Hsu, H.P.; Chen, L.T.; Lin, C.Y.; Tai, C.; Lin, C.M.; Li, C.F. HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer, 2012, 12, 611.
[77]
Lopez de Silanes, I.; Lal, A.; Gorospe, M. HuR: post-transcriptional paths to malignancy. RNA Biol., 2005, 2(1), 11-13.
[78]
Mazan-Mamczarz, K.; Hagner, P.R.; Corl, S.; Srikanta, S.; Wood, W.H.; Becker, K.G.; Gorospe, M.; Kenne, J.D.; Levenson, A.S.; Gartenhaus, R.B. Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene, 2008, 27(47), 6151-6163.
[79]
Malumbres, M.; Barbacid, M. Cell Cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer, 2009, 9(3), 153-166.
[80]
Ohtani, N.; Mann, D.J.; Hara, E. Cellular senescence: Its role in tumor suppression and aging. Cancer Sci., 2009, 100(5), 792-797.
[81]
Wang, W.; Yang, X.; Cristofalo, V.J.; Holbrook, N.J.; Gorospe, M. Loss of HuR is linked to reduced expression of proliferative genes during replicative senescence. Mol. Cell. Biol., 2001, 21(17), 5889-5898.
[82]
Musgrove, E.A.; Lee, C.S.; Buckley, M.F.; Sutherland, R.L. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA, 1994, 91(17), 8022-8026.
[83]
Hwang, H.C.; Clurman, B.E. Cyclin E in normal and neoplastic cell cycles. Oncogene, 2005, 24(17), 2776-2786.
[84]
Guo, X.; Hartley, R.S. HuR contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res., 2006, 66(16), 7948-7956.
[85]
Wang, W.; Caldwell, M.C.; Lin, S.; Furneaux, H.; Gorospe, M. HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J., 2000, 19(10), 2340-2350.
[86]
Kim, H.H.; Yang, X.; Kuwano, Y.; Gorospe, M. Modification at HuR (S242) alters HuR localization and proliferative influence. Cell Cycle, 2008, 7(21), 3371-3377.
[87]
Kim, H.H.; Gorospe, M. Phosphorylated HuR shuttles in cycles. Cell Cycle, 2008, 7(20), 3124-3126.
[88]
Kullmann, M.; Gopfert, U.; Siewe, B.; Hengst, L. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5’UTR. Genes Dev., 2002, 16(23), 3087-3099.
[89]
Wang, X.; Gorospe, M.; Huang, Y.; Holbrook, N.J. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene, 1997, 15(24), 2991-2997.
[90]
Lee, J.H.; Jung, M.; Hong, J.; Kim, M.K.; Chung, I.K. Loss of RNA-binding protein HuR facilitates cellular senescence through posttranscriptional regulation of TIN2 mRNA. Nucleic Acids Res., 2018, 46(8), 4271-4285.
[91]
Ghisolfi, L.; Calastretti, A.; Franzi, S.; Canti, G.; Donnini, M.; Capaccioli, S.; Nicolin, A.; Bevilacqua, A. B cell lymphoma (Bcl)-2 protein is the major determinant in bcl-2 adenine-uridine-rich element turnover overcoming HuR activity. J. Biol. Chem., 2009, 284(31), 20946-20955.
[92]
Cui, J.; Placzek, W.J. Post-transcriptional regulation of anti-apoptotic BCL2 family members. Int. J. Mol. Sci., 2018, 19(1), 308.
[93]
Abdelmohsen, K.; Lal, A.; Kim, H.H.; Gorospe, M. Posttranscriptional orchestration of an anti-apoptosis program by HuR. Cell Cycle, 2007, 6(11), 1288-1292.
[94]
Abdelmohsen, K.; Pullmann, P., Jr; Lal, A.; Kim, H.H.; Galban, S.; Yang, X.; Blethrow, J.D.; Walker, M.; Shubert, J.; Gillespie, D.A.; Furneaux, H.; Gorospe, M. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol. Cell, 2007, 25(4), 543-557.
[95]
Lafarga, V.; Cuadrado, A.; Lopez de Silanes, I.; Bengoechea, R.; Fernandez-Capetillo, O.; Nebreda, A.R. p38 mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. Mol. Cell. Biol., 2009, 29(16), 4341-4351.
[96]
Kim, H.H.; Kuwano, Y.; Srikantan, S.; Lee, E.K.; Martindale, J.L.; Gorospe, M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev., 2009, 23(15), 1743-1748.
[97]
Wang, W.; Furneaux, H.; Cheng, H.; Caldwell, M.C.; Hutter, D.; Liu, Y.; Holbrook, N.; Gorospe, M. HuR regulates p21 mRNA stabilization by UV light. Mol. Cell. Biol., 2000, 20(3), 760-769.
[98]
Fernau, N.S.; Fugmann, D.; Leyendecker, M.; Reimann, K.; Grether-Beck, S.; Galban, S.; Ale-Agha, N.; Krutmann, J.; Klotz, L.O. Role of HuR and p38MAPK in ultraviolet B-induced post-transcriptional regulation of COX-2 expression in the human keratinocyte cell line HaCaT. J. Biol. Chem., 2010, 285(6), 3896-3904.
[99]
Subbaramaiah, K.; Marmo, T.P.; Dixon, D.A.; Dannenberg, A.J. Regulation of cyclooxygenase-2 mRNA stability by taxanes: Evidence for involvement of p38, MAPKAPK-2, and HuR. J. Biol. Chem., 2003, 278(39), 37637-37647.
[100]
Lafarga, V.; Cuadrado, A.; Lopez De Silanes, I.; Bengocchea, R.; Fernandez-Capetillo, O.; Nebreda, A.R. p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. Mol. Cell. Biol., 2009, 29(16), 4341-4351.
[101]
King, F.W.; Shtivelman, E. Inhibition of nuclear import by the proapoptotic protein CC3. Mol. Cell. Biol., 2004, 24(16), 7091-7101.
[102]
Zhao, J.; Chen, J.; Lu, B.; Dong, L.; Wang, H.; Bi, C.; Wu, G.; Guo, H.; Wu, M.; Guo, Y. TIP30 induces apoptosis under oxidative stress through stabilization of p53 messenger RNA in human hepatocellular carcinoma. Cancer Res., 2008, 68(11), 4133-4141.
[103]
Klotz, L.O. Reactive Oxygen Species as Initiators and Mediators of Cellular Signaling Processes. In: Studies on Experimental Toxicology and Pharmaology; Roberts, S.M.; Kehrer, J.P.; Klotz, L.O., Eds.; Humana Press. New York. 2015, pp. 149-172.
[104]
Benoit, R.M.; Meisner, N.C.; Kallen, J.; Graff, P.; Hemmig, R.; Cebe, R.; Osterneier, C.; Widner, H.; Auer, M. The x-ray crystal structure of the first RNA recognition motif and site-directed mutagenesis suggest a possible HuR redox sensing mechanism. J. Mol. Biol., 2010, 397(5), 1231-1244.
[105]
Levy, N.S.; Chung, S.; Furneaux, H.; Levy, A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem., 1998, 273(11), 6417-6423.
[106]
Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2000, 2(3), 161-174.
[107]
Deryugina, E.I.; Quigley, J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev., 2006, 25(1), 9-34.
[108]
Clark, J.C.; Thomas, D.M.; Choong, P.F.; Dass, C.R. RECK – a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev., 2007, 26(3-4), 675-683.
[109]
Akool, el-S.; Kleinert, H.; Hamada, F.M.; Abdelwahab, M.H.; Forstermann, U.; Pfeilschifter, J.; Eberhardt, W. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol. Cell. Biol., 2003, 23(14), 4901-4916.
[110]
Huwiler, A. Akool, el-S.; Aschrafi, A.; Hamada, F.M.; Pfeilschifter, J.; Eberhardt, W. ATP potentiates interleukin-1 beta-induced MMP-9 expression in mesangial cells via recruitment of the ELAV protein HuR. J. Biol. Chem., 2003, 278(51), 51758-51769.
[111]
Mahmood, N.; Mihalcioiu, C.; Rabbani, S.A. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, prognostic, and therapeutic applications. Front. Oncol., 2018, 8, 24.
[112]
Mazar, A.P. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin. Cancer Res., 2008, 14, 5649-5655.
[113]
Tran, H.; Maurer, F.; Nagamine, Y. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol. Cell. Biol., 2003, 23(20), 7177-7188.
[114]
D’Alessio, S.; Blasi, F. The urokinase receptor as an entertainer of signal transduction. Front. Biosci., 2009, 14, 4575-4587.
[115]
Mauro, C.D.; Pesapane, A.; Formisano, L.; Rosa, R.; D’Amato, V.; Ciciola, P.; Servetto, A.; Marciano, R.; Orsini, R.C.; Monteleone, F.; Zambrano, N.; Fontanini, G.; Servadio, A.; Pignataro, G.; Grumetto, L.; Lavecchia, A.; Bruzzese, D.; Iaccarino, A.; Troncone, G.; Veneziani, B.M.; Montuori, N.; Placido, S.; Bianco, R. Uorkinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci. Rep., 2017, 7, 9388.
[116]
Dong, R.; Lu, J.G.; Wang, Q.; He, X.L.; Chu, Y.K. Stabilization of Snail by HuR in the process of hydrogen peroxide induced cell migration. Biochem. Biophys. Res. Commun., 2007, 356, 318-321.
[117]
Pu, J.; Zhang, X.; Luo, H.; Xu, L.; Lu, X.; Lu, J. Adrenaline promotes epithelial-to-mesenchymal transition via HuR-TGFβ regulatory axis in pancreatic cancer cells and the implication in cancer prognosis. Biochem. Biophys. Res. Commun., 2017, 493, 1273-1279.
[118]
Kuwano, Y.; Kim, H.H.; Abdelmohsen, K.; Pullmann, R., Jr; Martindale, J.L. MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90. Mol. Cell. Biol., 2008, 28, 4562-4575.
[119]
Keyse, S.M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev., 2008, 27(2), 253-261.
[120]
Wang, X.; Liu, Y. Regulation of innate immune response by MAP kinase phosphatase-1. Cell. Signal., 2007, 19(7), 1372-1382.
[121]
Bierie, B.; Moses, H.L. Tumor microenvironment: TGFbeta the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer, 2006, 6(7), 506-520.
[122]
Derynck, R.; Akhurst, R.J.; Balmain, A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet., 2001, 29(2), 117-129.
[123]
Beck, C.; Schreiber, H.; Rowley, D. Role of TGF-beta in immune-evasion of cancer. Microsc. Res. Tech., 2001, 52(4), 387-395.
[124]
Torre-Amione, G.; Beauchamp, R.D.; Koeppen, H.; Park, B.H.; Schreiber, H.; Moses, H.L.; Rowley, D.A. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA, 1990, 87(4), 1486-1490.
[125]
Hong, S. RNA binding protein as an emerging therapeutic target for cancer prevention and treatment. J. Cancer Prev., 2017, 22(4), 203-210.
[126]
Brennan, S.E.; Kuwano, Y.; Alkharouf, N.; Blackshear, P.J.; Gorospe, M.; Wilson, G.M. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res., 2009, 69(12), 5168-5176.
[127]
Hitti, E.; Bakheet, T.; Al-Souhibani, N.; Moghrabi, W.; Al-Yahya, S.; Al-Ghamdi, M.; Al-Saif, M.; Shoukri, M.M.; Lanczky, A.; Grepin, R.; Gyorffy, B.; Pages, G.; Khabar, K.S. Systematic analysis of AU-rich element expression in cancer reveals common functional clusters regulated by key RNA-binding proteins. Cancer Res., 2016, 76(14), 4068-4080.
[128]
Kim, I.; Kwak, H.; Lee, H.K.; Hyun, S.; Jeong, S. β-Catenin recognizes a specific RNA motif in the cyclooxygenase-2 mRNA 3′-UTR and interacts with HuR in colon cancer cells. Nucleic Acids Res., 2012, 40(14), 6863-6872.
[129]
Ahuja, D.; Goyal, A.; Ray, P.S. Interplay between RNA-binding protein HuR and microRNA-125b regulates p53 mRNA translation in response to genotoxic stress. RNA Biol., 2016, 13(11), 1152-1165.
[130]
Poria, D.K.; Guha, A.; Nandi, I.; Ray, P.S. RNA-binding protein HuR sequesters microRNA-21 to prevent translation repression of proinflammatory tumor suppressor gene programmed cell death 4. Oncogene, 2016, 35(13), 1703-1715.
[131]
Gunzburg, M.J.; Sivakumaran, A.; Pendini, N.R.; Yoon, J.H.; Gorospe, M.; Cj Wilce, M.; Wilce, J.A. Cooperative interplay of let-7 mimic and HuR with MYC RNA. Cell Cycle, 2015, 14(17), 2729-2733.
[132]
Kundu, P.; Fabian, M.R.; Sonenberg, N.; Bhattacharyya, S.N.; Filipowicz, W. HuR protein attenuates miRNA-mediated repression by promoting miRISC disccoiation from the target RNA. Nucleic Acids Res., 2012, 40(11), 5088-5100.
[133]
Kotta-Loizou, I.; Giaginis, C.; Theocharis, S. Clinical significance of HuR expression in human malignancy. Med. Oncol., 2014, 31(9), 161.
[134]
Wang, J.; Guo, Y.; Chu, H.; Guan, Y.; Bi, J.; Wang, B. Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. Int. J. Mol. Sci., 2013, 14(5), 10015-10041.
[135]
Zucal, C.; D’Agostino, V.; Loffredo, R.; Mantelli, B.; Natthakan, T.; Lal, P.; Latorre, E.; Provenzani, A. Targeting the multifaceted HuR protein, benefits and caveats. Curr. Drug Targets, 2015, 16(5), 499-515.
[136]
Blanco, F.F.; Jimbo, M.; Wulfkuhle, J.; Gallagher, I.; Deng, J.; Enyenihi, L.; Meisner-Kober, N.; Londin, E.; Rigoutsos, I.; Sawicki, J.A.; Risbud, M.V.; Witkiewicz, A.K.; McCue, P.A.; Jiang, W.; Rui, H.; Yeo, C.J.; Petricoin, E.; Winter, J.M.; Brody, J.R. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene, 2016, 35(19), 2529-2541.
[137]
McAllister, F.; Pineda, D.M.; Jimbo, M.; Lal, S.; Burkhart, R.A.; Moughan, J.; Winter, K.A.; Abdelmohsen, K.; Gorospe, M.; de Jesus Acosta, A.; Lankapalli, R.H.; Winter, J.M.; Yeo, C.J.; Witkiewicz, A.K.; Iacobuzio-Donahue, C.A.; Laheru, D.; Brody, J.R. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer. Cancer Biol. Ther., 2014, 15(6), 688-698.
[138]
Pineda, D.M.; Rittenhouse, D.W.; Valley, C.C.; Cozzitorto, J.A.; Burkhart, R.; Leiby, B.; Winter, J.M.; Weber, M.C.; Londin, E.R.; Rigoutsos, I.; Yeo, C.J.; Gorospe, M.; Witkiewicz, A.K.; Sachs, J.N.; Brody, J.R. HuR’s post-transcriptional regulation of death receptor 5 in pancreatic cancer cells. Cancer Biol. Ther., 2012, 13(10), 946-955.
[139]
Richards, N.G.; Rittenhouse, D.W.; Freydin, B.; Cozzitorto, J.A.; Grenda, D.; Rui, H.; Gonye, G.; Kennedy, E.P.; Yeo, C.J.; Brody, J.R.; Witkiewicz, A.K. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann. Surg., 2010, 252(3), 499-505.
[140]
Costantino, C.L.; Witkiewicz, A.K.; Kuwano, Y. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res., 2009, 69(11), 4567-4572.
[141]
Tatarian, T.; Jiang, W.; Leiby, B.E.; Grigoli, A.; Jimbo, M.; Dabbish, N.; Neoptolemos, J.P.; Greenhalf, W.; Costello, E.; Ghaneh, P.; Halloran, C.; Palmer, D.; Buchler, M.; Yeo, C.J.; Winter, J.M.; Brody, J.R. Cytoplasmic HuR status predicts disease-free survival in resected pancreatic cancer. Ann. Surg., 2018, 267(2), 364-369.
[142]
Vigouroux, C.; Casse, J.M.; Battaglia-Hsu, S.F.; Brochin, L.; Luc, A.; Paris, C.; Lacomme, S.; Gueant, J.L.; Vignaud, J.M.; Gauchotte, G. Methyl(R217)HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinoma. Lung Cancer, 2015, 89(2), 189-196.
[143]
Lal, S.; Burkhart, R.A.; Beeharry, N.; Bhattacharjee, V.; Londin, E.R.; Cozzitorto, J.A.; Romeo, C.; Jimbo, M.; Norris, Z.A.; Yeo, C.J.; Sawicki, J.A.; Winter, J.M.; Rigoutsos, I.; Yen, T.J.; Brody, J.R. HuR posttranscriptionally regulates WEE1: Implications for the DNA damage response in pancreatic cancer cells. Cancer Res., 2014, 74(4), 1128-1140.
[144]
Jimbo, M.; Blanco, F.F.; Huang, Y.H.; Telonis, A.G.; Screnci, B.A.; Cosma, G.L.; Alexeev, V.; Gonye, G.E.; Yeo, C.J.; Sawicki, J.A.; Winter, J.M.; Brody, J.R. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. Oncotarget, 2015, 6(29), 27312-27331.
[145]
Magnuson, N.S.; Wang, Z.; Ding, G.; Reeves, R. Why target PIM1 for cancer diagnosis and treatment? Future Oncol., 2010, 6(9), 1461-1478.
[146]
Chand, S.N.; Zarei, M.; Schiewer, M.J.; Kamath, A.R.; Romeo, C.; Lal, S.; Cozzitorto, J.A.; Nevler, A.; Scolaro, L.; Londin, E.; Jiang, W.; Meisner-Kober, N.; Pishvaian, M.J.; Knudsen, K.E.; Yeo, C.J.; Pascal, J.M.; Winter, J.M.; Brody, J.R. Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors. Cancer Res., 2017, 77(18), 5011-5025.
[147]
Zarei, M.; Lal, S.; Parker, S.J.; Nevler, A.; Vaziri-Gohar, A.; Dukleska, K.; Mambelli-Lisboa, N.C.; Moffat, C.; Blanco, F.F.; Chand, S.N.; Jimbo, M.; Cozzitorto, J.A.; Jiang, W.; Yeo, C.J.; Londin, E.R.; Seifert, E.L.; Metallo, C.M.; Brody, J.R.; Winter, J.M. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells. Cancer Res., 2017, 77(16), 4460-4471.
[148]
Jakstaite, A.; Maziukiene, A.; Silkuniene, G.; Kmieliute, K.; Gulbinas, A.; Dambrauskas, Z. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World J. Gastroenterol., 2018, 21(46), 13004-13019.
[149]
Satoh, K.; Kaneko, K.; Hirota, M.; Masamune, A.; Satoh, A.; Shimosegawa, T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas, 2001, 23(3), 251-258.
[150]
Romeo, C.; Weber, M.C.; Zarei, M.; DeCicco, D.; Chand, S.N.; Lobo, A.D.; Winter, J.M.; Sawicki, J.A.; Sachs, J.N.; Meisner-Kober, N.; Yeo, C.J.; Vadigepalli, R.; Tykocinski, M.L.; Bridy, J.R. HuR contributes to TRAIL resistance by restricting death receptor 4 expression in pancreatic cancer cells. Mol. Cancer Res., 2016, 14(7), 599-611.
[151]
To, K.K.; Leung, W.W.; Ng, S.S. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp. Cell Res., 2015, 338(2), 222-231.
[152]
Badawi, A.; Biyanee, A.; Nasrullah, U.; Winslow, S.; Schmid, T.; Pfeilschifter, J.; Eberhardt, W. Inhibition of IRES-dependent translation of caspase-2 by HuR confers chemotherapeutic drug resistance in colon carcinoma cells. Oncotarget, 2018, 9(26), 18367-18385.
[153]
Bonzon, C.; Bouchier-Hayes, L.; Pagliari, L.J.; Green, D.R.; Newmeyer, D.D. Caspase-2-induced apoptosis requires bid cleavage: A physiological role for bid in heat shock-induced death. Mol. Biol. Cell, 2006, 17(5), 2150-2157.
[154]
Von Roretz, C.; Lian, X.J.; Macri, A.M.; Punjani, N.; Clair, E.; Drouin, O.; Dormoy-Raclet, V.; Ma, J.F.; Gallouzi, I.E. Apoptotic-induced cleavage shifts HuR from being a promoter of survival to an activator of caspase-mediated apoptosis. Cell Death Differ., 2013, 20(1), 154-168.
[155]
Janakiraman, H.; House, R.P.; Talwar, S.; Courtney, S.M.; Hazard, E.S.; Hardiman, G.; Mehrotra, S.; Howe, P.H.; Gangaraju, V.; Palanisamy, V. Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma. Oncogene, 2017, 36(22), 3137-3148.
[156]
Zhou, Y.; Chang, R.; Ji, W.; Wang, N.; Qi, M.; Xu, Y.; Guo, J.; Zhan, L. Loss of scribble promotes Snail translation through translocation of HuR and enhances cancer drug resistance. J. Biol. Chem., 2016, 291(1), 291-302.
[157]
Ghosh, M.; Aguila, H.L.; Michaud, J.; Ai, Y.; Wu, M.T.; Hemmes, A.; Ristimaki, A.; Guo, C.; Furneaux, H.; Hla, T. Essential role of the RNA-binding protein HuR in progenitor cell survival in mice. J. Clin. Invest., 2009, 119(12), 3530-3543.
[158]
Katsanou, V.; Milatos, S.; Yiakouvaki, A.; Sgantzis, N.; Kotsoni, A.; Alexiou, M.; Harokopos, V.; Aidinis, V.; Hemberger, M.; Kontoyiannia, D.L. The RNA-binding protein Elav1/HuR is essential for placental branching morphogenesis and embryonic development. Mol. Cell. Biol., 2009, 29(10), 2762-2776.
[159]
Estep, J.A.; Sternburg, E.L.; Sanchez, G.A.; Karginov, F.V. Immunoblot screening of CRISPR/Cas9-mediated gene knockouts without selection. BMC Mol. Biol., 2016, 17, 9.
[160]
Giammanco, A.; Blanc, V.; Montenegro, G.; Klos, C.; Xie, Y.; Kennedy, S.; Luo, J.; Chang, S.H.; Hla, T.; Nalbantoglu, I.; Dharmarajan, S.; Davidson, N.O. Intestinal epithelial HuR modulates distinct pathways of proliferation and apoptosis and attenuates small intestinal and colonic tumor development. Cancer Res., 2014, 74(18), 5322-5335.
[161]
Yiakouvaki, A.; Dimitriou, M.; Karakasiliotis, I.; Eftychi, C.; Theocharis, S.; Kontoyiannis, D.L. Myeloid cell expression of the RNA-binding protein HuR protects mice from pathologic inflammation and colorectal carcinogenesis. J. Clin. Invest., 2012, 122(1), 48-61.
[162]
Weiss, W.A.; Taylor, S.S.; Shokat, K.M. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat. Chem. Biol., 2007, 3(12), 739-744.
[163]
Wang, H.; Zeng, F.; Liu, Q.; Liu, H.; Liu, Z.; Niu, L.; Teng, M.; Li, X. The structure of the ARE-binding domains of Hu Antigen R (HuR) undergoes conformational changes during RNA binding. Acta Crystallogr. Sect. D: Biol. Crystallogr., 2013, 69(Pt 3), 373-380.
[164]
Scheiba, R.M.; de-Opakua, A.L.; Diaz-Quintana, A.; Cruz-Gallardo, L.; Martinez-Chantar, M.L.; Blanco, F.J.; Diaz-Moreno, I. The C-terminal RNA binding motif of HuR is a multi-functional domain leading to HuR oligomerization and binding to U-rich RNA targets. RNA Biol., 2014, 11(10), 1250-1261.
[165]
Diaz-Quintana, A.; Garcia-Maurino, S.M.; Diaz-Moreno, I. Dimerization model of the C-terminal RNA recognition motif of HuR. FEBS Lett., 2015, 589(10), 1059-1066.
[166]
Meisner, N.C.; Hintersteiner, M.; Mueller, K.; Bauer, R.; Seifert, J.M.; Naegeli, H.C.; Ottl, J.; Oberer, L.; Guenat, C.; Moss, S.; Harrer, N.; Woisetchlaeger, M.; Buehler, C.; Uhl, V.; Auer, M. Identification and mechanistic characterization of low-molecular weight inhibitors of HuR. Nat. Chem. Biol., 2007, 3(8), 508-515.
[167]
Chae, M.J.; Sung, H.Y.; Kim, E.H.; Lee, M.; Kwak, H.; Chae, C.H.; Kim, S.; Park, W.Y. Chemical inhibitors destabilize HuR binding to the AU-rich element of TNF-alpha mRNA. Exp. Mol. Med., 2009, 41(11), 824-831.
[168]
Kwak, H.; Jeong, K.C.; Chae, M.J.; Kim, S.Y.; Park, W.Y. Flavonoids inhibit the AU-rich element binding of HuC. BMB Rep., 2009, 41(1), 41-46.
[169]
D’Agostino, V.G.; Adami, V.; Provenzani, A. A novel high throughput biochemical assay to evaluate the HuR protein-RNA complex formation. PLoS One, 2013, 8(8), e72426.
[170]
Wang, Z.; Bhattacharya, A.; Ivanov, D.N. Identification of small-molecule inhibitors of the HuR/RNA interaction using a fluorescence polarization screening assay followed by NMR validation. PLoS One, 2015, 10(9), e0138780.
[171]
Wu, X.; Lan, L.; Wilson, D.M.; Marquez, R.T.; Tsao, W.C.; Gao, P.; Roy, A.; Turner, B.A.; McDonald, P.; Tunge, J.A.; Rogers, S.A.; Dixon, D.A.; Aube, J.; Xu, L. Identification and validation of novel small molecule disruptors of HuR-mRNA interaction. ACS Chem. Biol., 2015, 10(6), 1476-1484.
[172]
D’Agostino, V.G.; Lal, P.; Mantelli, B.; Tiedje, C.; Zucal, C.; Thongon, N.; Gaestel, M.; Latorre, E.; Marinelli, L.; Seneci, P.; Amadio, M.; Provenzani, A. Dihydrotanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function. Sci. Rep., 2015, 5, 16478.
[173]
Lal, P.; Cerofolini, L.; D’Agostino, V.G.; Zucal, C.; Fuccio, C.; Bonomo, L.; Dassi, E.; Giuntini, S.; Di Maio, D.; Vishwakarma, V.; Preet, R.; Williams, S.N.; Fairlamb, M.S.; Munk, R.; Lehrmann, E.; Abdelmohsen, K.; Elezgarai, S.R.; Luchinat, C.; Novellino, E.; Quattrone, A.; Biasini, E.; Manzoni, L.; Gorospe, M.; Dixon, D.A.; Seneci, P.; Marinelli, L.; Fragai, M.; Provenzani, A. Regulation of HuR structure and function by dihydrotanshinone-I. Nucleic Acids Res., 2017, 45(16), 9514-9527.
[174]
Kaur, K.; Wu, X.; Fields, J.K.; Johnson, D.K.; Lan, L.; Pratt, M.; Somoza, A.D.; Wang, C.C.C.; Karanicolas, J.; Oakley, B.R. Xu, l.; De Guzman, R.N. The fungal natural product azaphilone-9 binds to HuR and inhibits HuR-RNA interaction in vitro. PLoS One, 2017, 12(4), e0175471.
[175]
Manzoni, L.; Zucal, C.; Di Maio, D.; D’Agostino, V.G.; Thongon, N.; Bonomo, I.; Lal, P.; Miceli, M.; Baj, V.; Brambilla, M.; Cerofolini, L.; Elezgarai, S.; Biasini, E.; Luchinat, C.; Novellino, E.; Fragai, M.; Marinelli, L.; Provenzani, A.; Seneci, P. Interfering with HuR-RNA interaction: Design, synthesis and biological characterization of tanshinone mimics as novel, effective HuR inhibitors. J. Med. Chem., 2018, 61(4), 1483-1498.
[176]
Muralidharan, R.; Mehta, M.; Ahmed, R.; Roy, S.; Xu, L.; Aube, J.; Chen, A.; Zhao, Y.D.; Herman, T.; Ramesh, R.; Munshi, A. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci. Rep., 2017, 7(1), 9694.
[177]
Nasti, R.; Rossi, D.; Amadio, M.; Pascale, A.; Unver, M.Y.; Hirsch, A.K.H.; Collina, S. Compounds interfering with Embryonic Lethal Abnormal Vision (ELAV) protein-RNA complexes: An avenue for discovering new drugs. J. Med. Chem., 2017, 60(20), 8257-8267.
[178]
Blanco, F.F.; Preet, R.; Aguado, A.; Vishwakarma, V.; Stevens, L.E.; Vyas, A.; Padhye, S.; Xu, L.; Weir, S.J.; Anant, S.; Meisner-Kober, N.; Brody, J.R.; Dixon, D.A. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget, 2016, 7(45), 74043-74058.
[179]
Lang, M.; Berry, D.; Passecker, K.; Mesteri, I.; Bhuju, S.; Ebner, F.; Sedlyarov, V.; Evstatiev, R.; Dammann, K.; Loy, A.; Kuzyk, O.; Kovarik, P.; Khare, V.; Beibel, M.; Roma, G.; Meisner-Kober, N.; Gasche, C. HuR small-molecule inhibitor elicits differential effects in adenomatosis polyposis and colorectal carcinogenesis. Cancer Res., 2017, 77(9), 2424-2438.
[180]
Guo, J.; Lv, L.; Chang, S.; Chen, Z.; Lu, W.; Xu, C.; Liu, M.; Pang, X. Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder. Oncotarget, 2016, 7(29), 45249-45262.
[181]
Li, B.; Flaveny, C.A.; Giambelli, C.; Fei, D.L.; Han, L.; Hang, B.I.; Bai, F.; Pei, X.H.; Nose, V.; Burlingame, O.; Capobianco, A.J.; Orton, D.; Lee, E.; Robbins, D.J. Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis. PLoS One, 2014, 9(7), e101969.
[182]
Lim, M.; Otto-Duessel, M.; He, M.; Su, L.; Nguyen, D.; Chin, E.; Alliston, T.; Jones, J.O. Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium. ACS Chem. Biol., 2014, 9(3), 692-702.
[183]
Sugimoto, K.; Hayakawa, F.; Shimada, S.; Morishita, T.; Shimada, K.; Katakai, T.; Tomita, A.; Kiyoi, H.; Naoe, T. Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Sci. Rep., 2015, 5, 13054.
[184]
Xu, W.; Lacerda, L.; Debeb, B.G.; Atkinson, R.L.; Solley, T.N.; Li, L.; Orton, D.; McMurray, J.S.; Hang, B.I.; Lee, E.; Klopp, A.H.; Ueno, N.T.; Reuben, J.M.; Krishnamurthy, S.; Woodward, W.A. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One, 2013, 8(8), e71508.
[185]
Muralidharan, R.; Babu, A.; Amreddy, N.; Srivastava, A.; Chen, A.; Zhao, Y.D.; Kompella, U.B.; Munshi, A.; Ramesh, R. Tumor-targeted nanoparticle delivery of HuR siRNA inhibits lung tumor growth in vitro and in vivo by disrupting the oncogenic activity of the RNA-binding protein HuR. Mol. Cancer Ther., 2017, 16(8), 1470-1486.
[186]
Muralidharan, R.; Babu, A.; Amreddy, N.; Basalingappa, K.; Mehta, M.; Chen, A.; Zhao, Y.D.; Kompella, U.B.; Munshi, A.; Ramesh, R. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J. Nanobiotechnology, 2016, 14(1), 47.
[187]
Huang, Y.H.; Peng, W.; Furuuchi, N.; Gerhart, J.; Rhodes, K.; Mukherjee, N.; Jimbo, M.; Gonye, G.E.; Brody, J.R.; Getts, R.C.; Sawicki, J.A. Delivery of therapeutics targeting the mRNA-binding protein HuR using 3DNA nanocarriers suppresses ovarian tumor growth. Cancer Res., 2016, 76(6), 1549-1559.
[188]
Muralidharan, R.; Panneerselvam, J.; Chen, A.; Zhao, Y.D.; Munshi, A.; Ramesh, R. HuR-targeted nanotherapy in combination with AMD3100 suppress CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther., 2015, 22, 581-590.
[189]
Lin, G.L.; Ting, H.J.; Tseng, T.C.; Juang, V.; Lo, Y.L. Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells. PLoS One, 2017, 12(10), e0185625.
[190]
Brody, J.R.; Gonye, G.E. HuR’s rule in gemcitabine efficacy: an exception or opportunity? Wiley Interdisc. Rev, 2011, 2(3), 435-444.
[191]
Lebedeva, S.; Jens, M.; Theil, K.; Schwanhausser, B.; Selbach, M.; Landthaler, M.; Rajewsky, N. Transcriptiome-wide analysis of regulatory interactions of the RNA-binding protein HuR. Mol. Cell, 2011, 43(3), 340-352.
[192]
Mukherjee, N.; Corcoran, D.L.; Nusbaum, J.D.; Reid, D.W.; Georgiev, S.; Hafner, M.; Ascano, M., Jr; Tuschl, T.; Ohler, U.; Keene, J.D. Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. Mol. Cell, 2011, 43(3), 327-339.
[193]
Kishore, S.; Jaskiewicz, L.; Burger, L.; Hausser, J.; Khorshid, M.; Zavolan, M. A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins. Nat. Methods, 2011, 8(7), 559-564.
[194]
Abdelmohsen, K.; Lal, A.; Kim, H.H.; Gorospe, M. Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle, 2007, 6(11), 1288-1292.
[195]
Ishimaru, D.; Ramalingam, S.; Sengupta, T.K.; Bandyopadhyay, S.; Dellis, S.; Tholanikunnel, B.G.; Fernandes, D.J.; Spicer, E.E.K. Regulation of Bcl-2 expression by HuR in HL60 leukemia cells and A431 carcinoma cells. Mol. Cancer Res., 2009, 7(8), 1354-1366.
[196]
Wang, J.; Zhao, W.; Guo, Y.; Zhang, B.; Xie, Q.; Xiang, D.; Gao, J.; Wang, B.; Chen, Z. The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis. Oncology, 2009, 76(6), 420-429.
[197]
Giles, K.M.; Daly, J.M.; Beveridge, D.J.; Thomson, A.M.; Voon, D.C.; Furneaux, H.M.; Jazayeri, J.A.; Leedman, P.J. The 3-untranslated region of p21WAF1 mRNA is a composite cis-acting sequence bound by RNA-binding proteins from breast cancer cells, including HuR and poly(C)-binding protein. J. Biol. Chem., 2003, 278(5), 2937-2946.
[198]
Yuan, Z.; Sanders, A.J.; Ye, L.; Wang, Y.; Jiang, W.G. Prognostic value of the human antigen R (HuR) in human breast cancer: High level predicts a favorable prognosis. Anticancer Res., 2011, 31(1), 303-310.
[199]
Luo, N.A.; Qu, Y.Q.; Yang, G.D.; Wang, T.; Li, R.L.; Jia, L.T.; Dong, R. Post-transcriptional up-regulation of PDGF-C by HuR in advanced and stressed breast cancer. Int. J. Mol. Sci., 2014, 15(11), 20306-20320.
[200]
Suswan, E.A. nabors, L.B.; Huang, Y.; Yang, X.; King, P.H. IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3′-untranslated region: Involvement of divergent RNA-binding factors HuR, KSPR and TIAR. Int. J. Cancer, 2005, 113(6), 911-919.
[201]
Woo, H.H.; Zhou, Y.; Yi, X.; David, C.L.; Zheng, W.; Gilmore-Hebert, M.; Kluger, H.M.; Ulukus, E.C.; Baker, T.; Stoffer, J.B. Chambers, S.K. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. Oncogene, 2009, 28(9), 1176-1186.
[202]
Topisirovic, I.; Siddiqui, N.; Orolicki, S.; Skrabanek, L.A.; Tremblay, M.; Hoang, T.; Borden, K.L. Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and its activity is dysregulated in cancer. Mol. Cell. Biol., 2009, 29(5), 1152-1162.
[203]
Del Vecchio, G.; De Vito, F.; Saunders, S.J.; Risi, A.; Mannironi, C.; Bozzoni, I.; Presutti, C. RNA-binding protein HuR and the members of the miR-200 family play an unconventional role in the regulation of c-Jun mRNA. RNA, 2016, 22(10), 1510-1521.
[204]
Hostetter, C.; Licata, L.A.; Witkiewicz, A.; Costantino, C.L.; Yeo, C.J.; Brody, J.R.; Kenn, J.C. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol. Ther., 2008, 7(9), 1496-1506.
[205]
Feng, X.; Shikama, Y.; Shichishima, T.; Noji, H.; Ikeda, K.; Ogawa, K.; Kimura, H.; Takeishi, Y.; Kimura, J. Impairment of FOS mRNA stabilization following translation arrest in granulocytes from myelodysplastic syndrome patients. PLoS One, 2013, 8(4), e61107.
[206]
Li, Y.; Yu, J.; Du, D.; Fu, S.; Chen, Y.; Yu, F.; Gao, P. Involvement of post-transcriptional regulation of FOXO1 by HuR in 5-FU-induced apoptosis in breast cancer cells. Oncol. Lett., 2013, 6(1), 156-160.
[207]
Licata, L.A.; Hostetter, C.L.; Crismale, J.; Sheth, A.; Keen, J. C. The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines. Breast Cancer Res. Treat., 2010, 122(1), 55-63.
[208]
Sheflin, L.G.; Zou, A.P.; Spaulding, S.W. Androgens regulate the binding of endogenous HuR to the AU-rich 3’UTRs of HIF-1alpha and EGF mRNA. Biochem. Biophys. Res. Commun., 2004, 322(2), 644-651.
[209]
Yang, F.; Miao, L.; Mei, Y.; Wu, M. Retinoic acid-induced HOXA5 expression is co-regulated by HuR and miR-130a. Cell. Signal., 2013, 25(6), 1476-1485.
[210]
Heinonen, M.; Hemmes, A.; Salmenkivi, K.; Abdelmohsen, K.; Vilen, S.T.; Laakso, M.; Leidenius, M.; Salo, T.; Hautaniemi, S.; Gorospe, M.; Heikkila, P.; Haglund, C.; Ristimaki, A. Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J. Pathol., 2011, 224(4), 529-539.
[211]
Zhu, Z.; Wang, B.; Bi, J.; Zhang, C.; Guo, Y.; Chu, H.; Liang, X.; Zhong, C.; Wang, J. Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer. Tumour Biol., 2013, 34(4), 2299-2308.
[212]
Heinonen, M.; Fagerholm, R.; Aaltonen, K.; Kilpivaara, O.; Aittomaki, K.; Blomqvist, C.; Heikkila, P.; Haglund, C.; Nevanlinna, H.; Ristimaki, A. Prognostic role of HuR in hereditary breast cancer. Clin. Cancer Res., 2007, 13(23), 6959-6963.
[213]
Saunus, J.M.; French, J.D.; Edwards, S.L.; Beveridge, D.J.; Hatchell, E.C.; Wagner, S.A.; Stein, S.R.; Davidson, A.; Simpson, K.J.; Francis, G.D.; Leedman, P.J.; Brown, M.A. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. Cancer Res., 2008, 68(22), 9469-9478.
[214]
Giaginis, C.; Sampani, A.; Kotta-Loizou, I.; Giannopoulou, I.; Danas, E.; Politi, E.; Tsourouflis, G.; Kouraklis, G.; Patsouris, E.; Keramopoulos, A.; Nakopoulou, L.; Theocharis, S. Elevated Hu-antigen receptor (HuR) expression is associated with tumor aggressiveness and poor prognosis but not with COX-2 expression in invasive breast carcinoma patients. Pathol. Oncol. Res., 2018, 24(3), 631-640.
[215]
Zhang, C.; Xue, G.; Bi, J.; Geng, M.; Chu, H.; Guan, Y.; Wang, J.; Wang, B. Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma. Tumour Biol., 2014, 35(1), 73-80.
[216]
Sun, D.P.; Lin, C.Y.; Tian, Y.F.; Chen, L.T.; Lin, L.C.; Lee, S.W.; Hsing, C.H.; Lee, H.H.; Shiue, Y.L.; Huang, H.Y.; Li, C.F.; Liang, P.I. Clinicopathological significance of HuR expression in gallbladder carcinoma: with special emphasis on the implications of its nuclear and cytoplasmic expression. Tumour Biol., 2013, 34(5), 3059-3069.
[217]
Wei, Y.C.; Chou, F.F.; Li, C.F.; Li, W.M.; Chen, Y.Y.; Lan, J.; Li, S.H.; Fang, F.M.; Hu, T.H.; Yu, S.C.; Eng, H.L.; Uen, Y.H.; Tian, Y.F.; Wang, J.C.; Huang, H.Y. HuR cytoplasmic expression is associated with increased cyclin A expression and inferior disease-free survival in patients with gastrointestinal stromal tumours (GISTs). Histopathology, 2013, 63(4), 445-454.
[218]
Gauchotte, G.; Hergalant, S.; Vigouroux, C.; Casse, J.M.; Houlgatte, R.; Kaoma, T.; Helle, D.; Brochin, L.; Rech, F.; Peyre, M.; Labrousse, F.; Vallar, L.; Gueant, J.L.; Vignaud, J.M.; Battaglia-Hsu, S.F. Cytoplasmic overexpression of RNA-binding protein HuR is a marker of poor prognosis in meningioma, and HuR knockdown decreases meningioma cell growth and resistance to hypoxia. J. Pathol., 2017, 242(4), 421-434.
[219]
Cha, J.D.; Kim, H.K.; Cha, I.H. Cytoplasmic HuR expression: Correlation with cellular inhibitors of apoptosis protein-2 expression and clinicopathologic factors in oral squamous cell carcinoma cells. Head Neck, 2014, 36(8), 1168-1175.
[220]
Kim, K.Y.; Li, S.; Cha, J.D.; Zhang, X.; Cha, I.H. Significance of molecular markers in survival prediction of oral squamous cell carcinoma. Head Neck, 2012, 34(7), 929-936.
[221]
Davidson, B.; Holth, A.; Hellesylt, E.; Hadar, R.; Katz, B.; Trope, C.G.; Reich, R. HuR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival. Hum. Pathol., 2016, 48, 95-101.
[222]
Giaginis, C.; Alexandrou, P.; Delladetsima, I.; Karavokyros, I.; Danas, E.; Giagini, A.; Patsouris, E.; Theocharis, S. Clinical significance of Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human malignant and benign thyroid lesions. Pathol. Oncol. Res., 2016, 22(1), 189-196.
[223]
Liang, P.I.; Li, W.M.; Wang, Y.H.; Wu, T.F.; Wu, W.R.; Liao, A.C.; Shen, K.H.; Wei, Y.C.; Hsing, C.H.; Shiue, Y.L.; Haung, H.Y.; Hsu, H.P.; Chen, L.T. HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer, 2012, 12, 611.
[224]
Sun, L.; Zhang, S.; Jiang, Z.; Huang, X.; Wang, T.; Huang, X.; Li, H.; Zhang, L. Triptolide inhibits COX-2 expression by regulating mRNA stability in TNF-a-treated A549 cells. Biochem. Biophys. Res. Commun., 2011, 416(1-2), 99-105.
[225]
Cheng, Y.C.; Liou, J.P.; Kuo, C.C.; Lai, W.Y.; Shih, K.H.; Chang, C.Y.; Pan, W.Y.; Tseng, J.T.; Chang, J.Y. MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1a mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol. Cancer Ther., 2013, 12(7), 1202-1212.

Rights & Permissions Print Cite
Article Metrics
225
21
3
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy